View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Montea NV: 1 director

A director at Montea NV sold 63,000 shares at 63.500EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update July: Removing Fagron and Melexis, Adding...

Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...

Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
Jacob Mekhael ... (+6)
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste

Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONW...

: ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA

Thomas Vranken
  • Thomas Vranken

Onward Medical FIRST LOOK: ARC-EX filed for home use in US and CE mark...

Onward has submitted two key regulatory applications for its ARC-EX system, a non-invasive neurostimulation device designed to improve hand function after spinal cord injury. Following its US clinic-use approval in December 2024 and initial sales of ten units in Q1 2025, the company has now filed a 510(k) with the FDA to enable home use in the US and a CE mark application under MDR for commercialization in the EU. Onward expects both approvals by YE25. The company remains confident in meeting it...

Thomas Vranken
  • Thomas Vranken

Biotalys The planned Evoca-tion of a first US approval

Biotalys is a Belgian AgTech company developing protein-based biocontrols through its proprietary Agrobody Foundry platform. The company aims to replace traditional chemical pesticides with safer, sustainable alternatives. The company recently guided for market approval in the US for its lead product Evoca by the end of September 2025, which would reflect an important value inflection point for the company. We have updated our model, and taking into account the expected near-term trigger, raise ...

 PRESS RELEASE

Progress on share buyback programme

Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €2.0 billion share buyback programme announced on 2 May 2025, in total 4,587,249 shares were repurchased during the week of 23 June 2025 up to and including 27 June 2025. The shares were repurchased at an average price of €18.20 for a total amount of €83,509,456.89. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at /investorrelations. In line with the purpose of the programme to reduce t...

 PRESS RELEASE

ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and...

ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application FDA 510(k) application submitted to allow marketing of the ARC-EX® System for home use in the United StatesCE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European Union and other countries EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord ...

Maxime Stranart
  • Maxime Stranart

Ontex/Another year of heavy restructuring ahead/HOLD (Change in primar...

We downgrade Ontex from Buy to HOLD and cut our target price from €13.83 to €8.2 following a change in primary analyst. We expect 2025 to be another year of heavy restructuring, leading to peak capex which is required, in our view, to modernise its industrial footprint and enable it to compete profitably on larger contracts going forwards. We see this limiting Ontex's organic growth in the short term to 2.7% in FY25F, despite capex on sales of c.6%. Although €115m in divestment proceeds is expec...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASR: Buyout deal, second in as many months, similar size (€660m). Flow Traders: Sticky digits. IMCD: Small but solid acquisition in India. Randstad: Preliminary preview of 2Q25F results due 23 July. UCB: Fintepla meets primary endpoint in CDKL5 Deficiency Disorder

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
Felix Fischer ... (+6)
  • Felix Fischer
  • Haidje Rustau
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Almaviva, Iliad, Ontex, Techem, Softbank Group, Sammontana Italia, Maxam Prill, Modulaire

 PRESS RELEASE

Ontex Group NV announces the redemption of the outstanding 3.500% seni...

Ontex Group NV announces the redemption of the outstanding 3.500% senior notes due 2026 Regulated information Aalst, Belgium, June 26, 2025 – Ontex Group NV (the “Issuer”) is pleased to announce that, pursuant to an unconditional notice of redemption dated June 26, 2025, it has notified the holders of the 3.500% Senior Notes due 2026 (ISIN: BE6329443962) (the “Notes”), that it will redeem all of its remaining outstanding Notes, plus accrued and unpaid interest and additional amounts, if any, on July 15, 2025. Following the cash tender offer launched in March and concluded in April 2026, wh...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch